OncoMatch/Clinical Trials/NCT06764485
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Is NCT06764485 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for metastatic castration-resistant prostate cancer.
Treatment: BMS-986365 · Enzalutamide · Abiraterone · Docetaxel · Predinsone/Prednisolone — The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Prior therapy
Must have received: androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, darolutamide)
previous treatment with an androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, or darolutamide)
Lab requirements
Cardiac function
must not have impaired cardiac function or clinically significant cardiac disease
Participants must not have impaired cardiac function or clinically significant cardiac disease.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Central Alabama Research · Birmingham, Alabama
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- Los Angeles Cancer Network (LACN) · Anaheim, California
- Moores Cancer Center · La Jolla, California
- Cancer and Blood Specialty Clinic · Los Alamitos, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify